S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CGEM · Cullinan Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Cullinan Therapeutics Inc (CGEM)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$14.88
+0.03
(+0.20%)
● At close: October 21 at 4:00:00 PM EDT
$15.00
+0.11
(+0.74%)
Overnight:
8:26:22 PM EDT
DAY'S RANGE
$14.88
$14.71
$15.26
52-WEEK RANGE
$14.88
$6.73
$23.19
What's happening
- CGEM is up 0.20% today, trading at $14.88. — Live quote
- Volume today (48,215) is well below its 3-month average of 964,390. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.81 actual vs. $-0.83 estimated (+1.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CGEM
+35.07%
vs S&P 500
+22.67%
1-YEAR RETURN
CGEM
+77.98%
vs S&P 500
+62.61%
6-MONTH RETURN
CGEM
-6.49%
3-MONTH RETURN
CGEM
-20.11%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.81
Est. $-0.83
BEAT +1.9%
2026-04-26 (Q1 2026)
$-0.75
Est. $-0.85
BEAT +11.3%
2026-01-26 (Q4 2025)
$-0.77
Est. $-0.83
BEAT +6.7%
2025-10-26 (Q3 2025)
$-0.77
Est. $-0.98
BEAT +21.1%
Valuation Measures & Ratios
Enterprise Value4$875.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)50.39
Price / Book73.48
EV4 / Revenue—
EV4 / EBITDA7.64
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-52.89%
Return on Assets (ROA9)-48.18%
Avg Volume (3M)964,390
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,634,127
Change from Prior Settlement-20.72%
% of Float—
Days to Cover (Short Ratio)5.07
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +78.0%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CGEM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$57.3M | -$53.7M | -$55.6M | -$75.8M | -$55.0M | -$48.9M | -$50.0M | -$43.0M |
| Net income | — | — | -$50.6M | -$70.1M | -$48.5M | -$40.6M | -$42.0M | -$37.1M |
| EPS (diluted) | — | — | — | — | — | $-0.69 | $-0.75 | $-0.86 |
| EPS (basic) | — | — | — | — | — | $-0.69 | $-0.75 | $-0.86 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $363.8M | $403.0M | $448.4M | $484.1M | $520.3M | $579.7M | $621.8M | $653.3M |
| Total liabilities | $42.0M | $36.8M | $39.6M | $32.8M | $28.2M | $27.8M | $31.5M | $25.4M |
| Stockholders' equity | — | — | $408.7M | $451.4M | $492.1M | $551.8M | $590.3M | $627.9M |
| Total current assets | $342.0M | $361.4M | $386.8M | $342.2M | $275.9M | $317.8M | $414.7M | $592.0M |
| Total current liabilities | $40.6M | $35.2M | $37.7M | $32.8M | $28.1M | $27.3M | $30.6M | $24.2M |
| Cash & equivalents | $78.6M | $75.1M | $88.3M | $103.3M | $72.8M | $76.7M | $83.0M | $102.1M |
| Marketable securities (current) | $255.9M | $276.8M | $289.6M | $229.3M | $192.7M | $227.2M | $316.0M | $476.0M |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $19.0M | $38.5M | $58.3M | $140.0M | $242.3M | $259.4M | $204.4M | $58.0M |
| Property, plant & equipment | $263.0K | $342.0K | $421.0K | $489.0K | $569.0K | $607.0K | $683.0K | $760.0K |
| Other non-current assets | $297.0K | $297.0K | $297.0K | $361.0K | $367.0K | $366.0K | $366.0K | $460.0K |
| Accounts payable | $3.7M | $2.5M | $841.0K | $1.7M | $2.5M | $3.4M | $1.7M | $2.1M |
| Accrued liabilities | $36.2M | $31.9M | $36.1M | $29.8M | $24.2M | $22.6M | $27.7M | $20.8M |
| Other current liabilities | $1.5M | $1.4M | $996.0K | $1.5M | $2.2M | $2.8M | $1.4M | $1.7M |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$691.5M | -$637.8M | -$588.1M | -$537.4M | -$486.8M | -$416.7M | -$368.2M | -$320.6M |
| Accumulated other comprehensive income (loss) | -$134.0K | $127.0K | $1.0M | $973.0K | $607.0K | $505.0K | -$133.0K | $970.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.2M | -$46.0M | -$38.1M | -$36.9M | -$57.6M | -$43.2M | -$36.6M | -$34.1M |
| Investing cash flow | $40.7M | $32.4M | $22.4M | $67.4M | $53.4M | $36.8M | $16.0M | $19.9M |
| Financing cash flow | $1.1M | $380.0K | $715.0K | $0 | $373.0K | $0 | $1.6M | $1.3M |
| Free cash flow | — | — | -$38.1M | -$36.9M | — | — | -$36.6M | -$34.1M |
| Capital expenditures | — | — | $11.0K | $38.0K | — | — | $0 | $0 |
| Depreciation & amortization | $79.0K | $79.0K | $79.0K | $79.0K | $77.0K | $76.0K | $77.0K | $76.0K |
| Share-based compensation | $8.4M | $7.6M | $7.3M | $9.5M | $9.9M | $9.4M | $9.6M | $9.4M |
| Deferred income taxes | — | — | — | — | — | — | $3.0M | — |
| Change in accounts payable | $1.2M | $1.7M | -$879.0K | -$739.0K | -$941.0K | $1.7M | -$434.0K | $560.0K |
| Purchases of investments | $14.6M | $20.1M | $19.6M | $12.6M | $78.5M | $125.8M | $168.0M | $96.8M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $18.9M |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M | -$68.0M |
| Net income | -$219.9M | -$167.4M | -$153.2M | $111.2M | -$65.6M |
| EPS (diluted) | — | — | $-3.69 | $2.38 | $-1.52 |
| EPS (basic) | — | — | $-3.69 | $2.46 | $-1.52 |
| Operating margin | — | — | — | — | -$359 |
| Net margin | — | — | — | — | -$346 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M | $11.8M |
| Stockholders' equity | $408.7M | $590.3M | $453.7M | $535.0M | $425.0M |
| Total current assets | $386.8M | $414.7M | $480.2M | $474.5M | $296.6M |
| Total current liabilities | $37.7M | $30.6M | $28.1M | $22.5M | $11.7M |
| Cash & equivalents | $88.3M | $83.0M | $98.4M | $156.2M | $59.8M |
| Marketable securities (current) | $289.6M | $316.0M | $368.6M | $311.1M | $230.7M |
| Other current assets | — | — | $3.9M | — | — |
| Marketable securities (non-current) | $58.3M | $204.4M | $0 | $80.9M | $140.4M |
| Property, plant & equipment | $421.0K | $683.0K | $989.0K | $1.2M | $77.0K |
| Other non-current assets | $297.0K | $366.0K | $459.0K | $459.0K | $147.0K |
| Accounts payable | $841.0K | $1.7M | $2.5M | $2.7M | $3.2M |
| Accrued liabilities | $36.1M | $27.7M | $24.2M | $14.1M | $8.6M |
| Other current liabilities | $996.0K | $1.4M | $914.0K | $2.0M | $973.0K |
| Common stock & paid-in capital | $6.0K | $6.0K | $4.0K | $5.0K | $4.0K |
| Retained earnings | -$588.1M | -$368.2M | -$200.9M | -$47.7M | -$158.9M |
| Accumulated other comprehensive income (loss) | $1.0M | -$133.0K | -$129.0K | -$2.6M | -$838.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.4M |
| Investing cash flow | $180.0M | -$136.3M | $35.8M | $249.0M | -$333.8M |
| Financing cash flow | $1.1M | $266.2M | $40.8M | -$25.9M | $268.8M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | -$43.4M |
| Capital expenditures | $49.0K | $0 | $208.0K | $1.1M | $0 |
| Depreciation & amortization | $311.0K | $306.0K | $310.0K | $93.0K | $53.0K |
| Share-based compensation | $36.0M | $37.8M | $30.4M | $28.0M | $24.4M |
| Deferred income taxes | — | $3.0M | $5.4M | — | $0 |
| Change in accounts payable | -$839.0K | -$812.0K | -$167.0K | -$509.0K | -$4.8M |
| Purchases of investments | $236.5M | $721.1M | $373.4M | $377.9M | $525.8M |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CGEM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers102.1%
Shares Outstanding61,972,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| MPM BioImpact LLC | 9,731,341 | $177.2M | 15.70% | +27.2% | 2026-08-14 |
| Lynx1 Capital Management LP | 8,963,500 | $163.2M | 14.46% | +0.0% | 2026-08-12 |
| BVF INC/IL | 5,750,683 | $104.7M | 9.28% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 5,232,766 | $95.3M | 8.44% | +17.6% | 2026-08-07 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,825,950 | $69.7K | 6.17% | +88.5% | 2026-08-14 |
| State Street Corp | 3,668,627 | $66.8M | 5.92% | +44.2% | 2026-08-07 |
| Kynam Capital Management, LP | 3,114,132 | $56.7M | 5.03% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,614,066 | $47.6M | 4.22% | +5.3% | 2026-06-30 |
| RTW INVESTMENTS, LP | 2,364,347 | $43.1M | 3.82% | +38.6% | 2026-08-14 |
| Siren, L.L.C. | 1,893,410 | $34.5M | 3.06% | +58.7% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,547,309 | $28.2M | 2.50% | +13.1% | 2026-08-12 |
| Blue Owl Capital Holdings LP | 1,539,764 | $28.0M | 2.48% | -19.4% | 2026-08-11 |
| Venrock Adviser, LLC | 1,379,965 | $25.1M | 2.23% | +0.0% | 2026-08-14 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1,082,611 | $19.7M | 1.75% | -2.7% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 1,046,694 | $19.1M | 1.69% | +15.5% | 2026-08-11 |
| Goldman Sachs Group Inc | 1,001,598 | $18.2M | 1.62% | +119.9% | 2026-08-14 |
| Affinity Asset Advisors, LLC | 875,760 | $15.9M | 1.41% | +12.1% | 2026-08-13 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 738,741 | $13.5M | 1.19% | +33.7% | 2026-06-30 |
| BOONE CAPITAL MANAGEMENT LLC | 704,442 | $12.8M | 1.14% | +0.0% | 2026-08-14 |
| Elmind Capital, LP | 690,000 | $12.6M | 1.11% | +30.2% | 2026-08-14 |
| Morgan Stanley | 629,035 | $11.5M | 1.02% | +6.7% | 2026-08-11 |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 595,489 | $10.8M | 0.96% | +0.0% | 2026-07-28 |
| AQR CAPITAL MANAGEMENT LLC | 581,338 | $10.6M | 0.94% | +61.1% | 2026-08-14 |
| Northern Trust Corp | 571,080 | $10.4M | 0.92% | +27.1% | 2026-08-12 |
| Bank Of America Corp /De/ | 510,325 | $9.3M | 0.82% | -1.2% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-24 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-13 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about CGEM (Cullinan Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
BTIG Research Reaffirms "Buy" Rating for Cullinan Therapeutics (NASDAQ:CGEM)
MarketBeat · 2026-10-21 -
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
Stock Traders Daily · 2026-10-21 -
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-20 -
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 6.7% - Still a Buy?
MarketBeat · 2026-10-19 -
BTIG reiterates Buy rating on Cullinan Therapeutics, $40 price target
TradingView · 2026-10-19 -
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Yahoo Finance · 2026-10-19 -
CGEM Nov 2026 18.000 put (CGEM261120P00018000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19
No headlines in this category right now — try “All”.